Jeremy Cooke

Stocks Editor at Bloomberg News

Featured in: Favicon

bloomberg.com Favicon

bbc.co.uk

yahoo.com

business-standard.com Favicon

newsmax.com Favicon

bqprime.com Favicon

bnnbloomberg.ca Favicon

bloomberglaw.com Favicon

bloombergtax.com Favicon

ndtv.com + 3 more

Articles

Lab Company Shares Dive as FDA Pivots Away From Animal Testing

1 week ago | news.bloomberglaw.com | Hari Govind |Jeremy Cooke

(Updates Charles River share move, adds other peers, AI movers, more details from FDA.) The FDA said it plans to phase out animal testing requirements for monoclonal antibodies and other drugs, replacing them with “more effective, human-relevant methods.” Shares in Charles River Laboratories, a leading provider of research animal models, plunged by a one-day record of 28% to the lowest since March 2020 Among other contract-research peers, LabCorp closed lower by 5.2%, while microcap stock...
Lab Company Shares Dive as FDA Pivots Away From Animal Testing

1 week ago | news.bloombergtax.com | Hari Govind |Jeremy Cooke

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Novavax Falls on Report Covid Shot Unlikely to Be Approved Soon

3 weeks ago | news.bloomberglaw.com | Jeremy Cooke

Novavax shares turned negative and fell as much as 5.1% after the Wall Street Journal said US regulators missed the deadline for granting full approval to the company’s Covid-19 vaccine. The stock has since pared its decline to 0.5%.
Novavax Falls on Report Covid Shot Unlikely to Be Approved Soon

3 weeks ago | news.bloombergtax.com | Jeremy Cooke

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Vaccine Stocks Jump on Report of New Coronavirus Study in China

2 months ago | news.bloombergtax.com | Jeremy Cooke

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Vaccine Stocks Jump on Report of New Coronavirus Study in China

2 months ago | news.bloomberglaw.com | Jeremy Cooke

Shares of Covid-19 vaccine makers spiked Friday afternoon in New York as traders shared earlier reports about a new coronavirus study in China.
Darling Falls on Report Biofuel Tax-Credit Guidance in Doubt (1)

Dec 3, 2024 | news.bloomberglaw.com | Airielle Lowe |Jeremy Cooke

(Adds Darling stock move starting in headline)Biden administration officials will not finalize guidelines on new clean fuel production tax credits aimed at the airline and biofuel industries before the end of Biden’s term in January, Reuters reports, citing three sources familiar with the matter.
Darling Falls on Report Biofuel Tax-Credit Guidance in Doubt (1)

Dec 3, 2024 | news.bloombergtax.com | Airielle Lowe |Jeremy Cooke

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Adaptimmune Underperforms After Roche Ends Collaboration

Apr 12, 2024 | news.bloombergtax.com | Jeremy Cooke

Adaptimmune-rte-company> is down 10% in New York trading, underperforming a 3.6% decline in the SPDR S&P Biotech ETF, after the cancer-therapy developer disclosed-bsp-bb-link> earlier Friday that its strategic collaboration with Roche’s Genentech, which dates to 2021, has been terminated. • ADAP reaffirmed its focus on potentially launching its afami-cel product for synovial sarcoma later this year after the FDA decision date on Aug.
Adaptimmune Underperforms After Roche Ends Collaboration

Apr 12, 2024 | news.bloombergtax.com | Jeremy Cooke

Adaptimmune is down 10% in New York trading, underperforming a 3.6% decline in the SPDR S&P Biotech ETF, after the cancer-therapy developer disclosed earlier Friday that its strategic collaboration with Roche’s Genentech, which dates to 2021, has been terminated. • ADAP reaffirmed its focus on potentially launching its afami-cel product for synovial sarcoma later this year after the FDA decision date on Aug.